Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea

被引：0
|
作者：
Eui-Soon Kim
Sun-Kyeong Park
Daniel Sung-ho Cho
Jong-Chan Youn
Hye Sun Lee
Hae-Young Lee
Hyun-Jai Cho
Jin-Oh Choi
Eun-Seok Jeon
Sang Eun Lee
Min-Seok Kim
Jae-Joong Kim
Kyung-Kuk Hwang
Myeong-Chan Cho
Shung Chull Chae
Seok-Min Kang
Jin Joo Park
Dong-Ju Choi
Byung-Su Yoo
Jae Yeong Cho
Kye Hun Kim
Byung-Hee Oh
Barry Greenberg
Sang Hong Baek
机构：
[1] Korea Advanced Institute of Science and Technology (KAIST),Graduate School of Medical Science and Engineering
[2] The Catholic University of Korea,College of Pharmacy
[3] The Catholic University of Korea,Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine
[4] Yonsei University College of Medicine,Biostatistics Collaboration Unit
[5] Seoul National University Hospital,Department of Internal Medicine
[6] Seoul National University School of Medicine,Department of Internal Medicine
[7] Sungkyunkwan University College of Medicine,Department of Internal Medicine, Asan Medical Center
[8] University of Ulsan College of Medicine,Department of Internal Medicine
[9] Chungbuk National University Hospital,Department of Internal Medicine
[10] Kyungpook National University College of Medicine,Department of Internal Medicine
[11] Yonsei University College of Medicine,Department of Internal Medicine
[12] Seoul National University Bundang Hospital,Department of Internal Medicine
[13] Yonsei University Wonju College of Medicine,Department of Cardiovascular Medicine
[14] Chonnam National University Medical School,Department of Cardiovascular Medicine
[15] Incheon Sejong Hospital,Department of Cardiology
[16] UC San Diego Health System,undefined
来源：
American Journal of Cardiovascular Drugs | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 324
页数：11
相关论文
共 50 条
  • [1] Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea
    Kim, Eui-Soon
    Park, Sun-Kyeong
    Cho, Daniel Sung-ho
    Youn, Jong-Chan
    Lee, Hye Sun
    Lee, Hae-Young
    Cho, Hyun-Jai
    Choi, Jin-Oh
    Jeon, Eun-Seok
    Lee, Sang Eun
    Kim, Min-Seok
    Kim, Jae-Joong
    Hwang, Kyung-Kuk
    Cho, Myeong-Chan
    Chae, Shung Chull
    Kang, Seok-Min
    Park, Jin Joo
    Choi, Dong-Ju
    Yoo, Byung-Su
    Cho, Jae Yeong
    Kim, Kye Hun
    Oh, Byung-Hee
    Greenberg, Barry
    Baek, Sang Hong
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (02) : 313 - 324
  • [2] Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction
    Kim, E. S.
    Park, S. K.
    Youn, J. C.
    Lee, H. Y.
    Kim, M. S.
    Choi, J. O.
    Kang, S. M.
    Yoo, B. S.
    Choi, D. J.
    Oh, B. H.
    Baek, S. H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 197 - 197
  • [3] Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 183 - 190
  • [4] Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
    Mendoza, Victor L.
    Tumanan-Mendoza, Bernadette A.
    Punzalan, Felix Eduardo R.
    ESC HEART FAILURE, 2021, 8 (06): : 5132 - 5141
  • [5] Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
    Mendoza, Victor L.
    Tumanan-Mendoza, Bernadette A.
    Punzalan, Felix Eduardo R.
    ESC HEART FAILURE, 2022, 8 (06): : 5132 - 5141
  • [6] Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
    Tang, Yi
    Sang, Haiqiang
    ESC HEART FAILURE, 2023, 10 (04): : 2524 - 2533
  • [7] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE IN PANAMA
    Ordonez, J.
    Gonzales, L.
    Romero, A.
    Effio, J.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S403 - S403
  • [8] Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
    Butt, Jawad H.
    Docherty, Kieran F.
    Claggett, Brian L.
    Desai, Akshay S.
    Fang, James C.
    Petersson, Magnus
    Langkilde, Anna Maria
    de Boer, Rudolf A.
    Honorio, Jose Walter Cabrera
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Kober, Lars
    Lam, Carolyn S. P.
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Vardeny, Orly
    O'Meara, Eileen
    Saraiva, Jose F. K.
    Shah, Sanjiv J.
    Vaduganathan, Muthiah
    Jhund, Pardeep S.
    Solomon, Scott D.
    McMurray, John J. V.
    JACC-HEART FAILURE, 2023, 11 (04) : 375 - 388
  • [9] Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
    Park, Sun-Kyeong
    Hong, Sung-Hyun
    Kim, HyoJin
    Kim, Sungju
    Lee, Eui-Kyung
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1066 - 1079
  • [10] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE IN COSTA RICA
    Ordonez, J.
    Quesada Chaves, D. F.
    Rodriguez, M.
    Poveda, J.
    Speranza, M.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S360 - S360
12345